789results about "Isotope introduction to organic compounds" patented technology

The invention relates to an organic molecule, in particular for the application in optoelectronic devices. According to the invention, the organic molecule includes or consists of a structure represented by Formula IwhereinR1 is selected from the group consisting of hydrogen and C6-C12-aryl, which is optionally substituted with one or more C1-C6-alkyl substituents, andRa is at each occurrence independently selected from the group consisting of: hydrogen, deuterium, N(R5)2, OR5, Si(R5)3, B(OR5)2, B(R5)2, OSO2R5, CF3, CN, F, Br, I, C1-C40-alkyl, C1-C40-alkoxy, C1-C40-thioalkoxy, C2-C40-alkenyl, C2-C40-alkynyl, C6-C60-aryl, and C2-C57-heteroaryl.

An organic light-emitting element according to the present invention employs a polycyclic aromatic derivative compound in a light-emitting layer inside the element, and further comprises a capping layer. Thus, the organic light-emitting element can be made highly efficient and can be useful for a device selected from among a flat panel display device, a flexible display device, a monochrome or white flat panel lighting device, and a monochrome or white flexible lighting device.

The present invention belongs to the technical field of radiopharmaceutical chemistry and nuclear medicine diagnosis and treatment and relates to a radiolabeled FAPI complex, a preparation method therefor, and a use thereof. The general structural formula of FAPI capable of realizing radionuclide labeling is as shown below: wherein R is a nitroimidazole group or -COOH; X is a chelating group or a chelating structure chelated with a radionuclide; L1 and L2 are linking groups; and A is an adjusting atom of an FAP-targeting group, and all the A atoms are H atoms or F atoms. The synthesis method for a radionuclide-labeled precursor of the present invention is simple and suitable for various nuclide labels, the labeling method is convenient, and the label has high radiochemical purity and good stability. The radiolabeled FAPI complex shows high affinity and specificity for FAP in a cell experiment and a high tumor uptake and target to non-target ratio in a tumor-bearing mouse, and is a potential FAP-targeting radioactive diagnosis and treatment drug.

A compound according to formula (I), wherein A is -As(OH) or an arsenoxide equivalent group; each of R, R, R, and R is independently selected from H, X, OH, NH, CO, SCN, -CHNH, -NHCOCH, -NHCOCHX, or NO; X is a halogen; R is -NHCHCOOH, OH, or OR; and R is C. 1-5 The present invention relates to compounds, or pharmaceutically acceptable salts, esters, prodrugs, or solvates thereof, uses of said compounds, and methods of preparing said compounds, and further relates to diagnostic methods utilizing said compounds.

The invention relates to organic electroluminescent materials and devices. There is provided a compound having the formula Ir (LA) x (LB) y (LC) z wherein x and y are each independently 1 or 2, z is 0 or 1, and x + y + z = 3; the first ligand LA comprises a structure as shown in a formula I; lB comprises a structure of formula II; and LC is a bidentate ligand. In these structures, each of the moieties A, C and D is a monocyclic or polycyclic fused ring system; each of X1-X7 and Z1-Z4 is C or N; y1 is a linking group; z is Si or Ge; and each substituent is hydrogen or a universal substituent as defined herein. Formulations, OLEDs, and consumer products containing the compounds are also provided. Further provided is a method of preparing a compound of formula M '(LA') p (LB ') q (LC') r as defined herein.

The present disclosure relates to compounds, compositions, and methods for treating diseases or disorders that are associated with aberrant tumor necrosis factor receptor 1 (TNFR1) signaling.

The present disclosure sets forth novel compounds and compositions including heteroaromatic silicon-fluoride-acceptors, which are useful for PET scanning. The present disclosure further includes novel methods of 18F imaging for PET scanning, the methods comprising the preparation of conjugates and bioconjugates of biological ligands of interest with heteroaromatic silicon-fluoride-acceptors. In certain embodiments the invention is practiced in the form of a kit.

Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer are disclosed.

The invention discloses a preparation method of methylboronic acid-d3, which comprises the following steps: taking iodomethane-d3 as a raw material, carrying out Grignard reaction on the iodomethane-d3 and magnesium chips to generate methyl magnesium iodine-d3, further reacting the methyl magnesium iodine-d3 and trimethyl borate to generate dimethyl methylboronic acid, adding acid, quenching, hydrolyzing, and purifying to obtain the methylboronic acid-d3. The product prepared by the method is high in purity, high in yield and high in deuteration degree.

The invention relates to a targeted fibroblast activating protein radiopharmaceutical, in particular to a compound which is a compound as shown in a formula I or a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug of the compound as shown in the formula I, the compounds can inhibit the expression of fibroblast activating protein FAP or diagnose and / or treat diseases characterized by overexpression of fibroblast activating protein. # imgabs0 #

The present disclosure relates to a boron compound applicable to an organic light-emitting diode and an organic light-emitting diode comprising same. More specifically, the present disclosure relates to a boron compound represented by any one of Chemical Formulas A to D and an organic light-emitting diode comprising same, wherein Chemical Formulas A to D are as defined in the description.

A compound comprising a first ligand LA of Formula I′,or Formula I*:In Formula I′ or Formula I*, all the variables are defined herein; and LA is coordinated to a metal M. Formulations, OLEDs, and consumer products containing the compound are also provided.

The invention relates to organic electroluminescent materials and devices. There is provided a compound having a first ligand LA having a structure of Formula I wherein consecutive two of X1 to X8 are C and bonded to the structure of Formula II in Formula I, Part A is a monocyclic or polycyclic fused ring system; each of Z1 to Z2 and X1 to X12 is C or N; each of Y1 and Y2 is a linking group; k is a direct bond or a linking group; each substituent is hydrogen or a universal substituent as defined herein; and LA is coordinated with the metal M. Also provided is a compound having the formula Ir (LA *) x (LB *) y (LC *) z as defined herein. Formulations, OLEDs and consumer products containing these compounds are further provided.

The invention provides a method for catalyzing hydrogen-deuterium replacement of heterocyclic aromatic hydrocarbon by using a binary cheap metal, and belongs to the technical field of organic synthesis.The method comprises the steps that a heterocyclic aromatic hydrocarbon compound serves as a raw material, heavy water and a binary cheap metal catalyst are added under the condition that a solvent is added or not added, under inert gas protection, heating is conducted for hydrogen-deuterium replacement reaction, and after the reaction is finished, a product is obtained; and separating and purifying the product to obtain the heterocyclic aromatic hydrocarbon deuterated compound. The preparation method provided by the invention adopts cheap heavy water as a deuterium source and cheap double-element metal as a catalyst, so that the cost is low, the operability is high, the applicability is wide, and the deuteration rate is high; a cheap and efficient heterocyclic aromatic hydrocarbon deuteration technology is realized, and the limitation of the existing heterocyclic aromatic hydrocarbon deuteration technology is solved.

A compound of Formula Ir(LA)x(LB)y(LC)z is provided where x and y are independently 1 or 2; z is 0 or 1; and x+y+z=3; first ligand LA includes a structure of Formula I,ligand LB includes a structure of Formula II:and ligand LC is a bidentate ligand. In the compounds, moiety B is a polycyclic fused ring system comprising at least four rings; each of moiety C and moiety D is a monocyclic ring or a polycyclic fused ring system; each of X1 to X4 and Z1 to Z6 is C or N; L0 is a direct bond or a linking group; YA is a linking group; each substituent is hydrogen or a General Substituent defined herein; and any two substituents may be joined or fused to form a ring. Formulations, OLEDs, and consumer products containing the compound are also provided.

Embodiments provide a light-emitting device and an electronic apparatus including the light-emitting device. The light-emitting device includes a first electrode, a second electrode facing the first electrode, and an interlayer between the first electrode and the second electrode, wherein the interlayer includes an emission layer. The emission layer includes a host, a first dopant, and a second dopant, wherein a weight percent of the first dopant is greater than a weight percent of the second dopant, and the weight percent of the first dopant increases from an interface of the emission layer towards a center of the emission layer.

The present invention provides a method for producing a deuterium compound, which allows the deuterium compound to be obtained efficiently. [Solution] A method for producing a deuterium compound includes a deuteration step of contacting a compound having at least one of an aromatic ring and a heterocycle with a deuterium source in the presence of a solvent and a catalyst, the solvent including at least one of 2-propanol and hexafluoro-2-propanol, the catalyst including iridium, and the deuterium source including at least one of heavy water and a deuterated solvent.

The present disclosure relates to an organometallic compound in Formula below and an organic light emitting diode and an organic light emitting device including the organometallic compound. The organometallic compound provides high emitting efficiency and longer lifespan, and the organic light emitting diode and the organic light emitting device have advantages in the emitting efficiency and the lifespan.

Disclosed are an organic electroluminescent material and a device thereof. The organic electroluminescent material is a polycyclic compound with a structure of formula 1, which can be used as a TADF material in an organic electroluminescent device. The polycyclic compound has a regulating effect on the emission color, can realize desired green light emission, has deeper HOMO and LUMO energy levels, has the potential to become an excellent light-emitting material, and has a very broad industrial application prospect. Also disclosed are an organic electroluminescent device comprising the compound and a compound composition comprising the compound.

The present disclosure relates to a compound, and an organic electroluminescent material and an organic electroluminescent device comprising the same. By comprising the compound and / or the organic electroluminescent material according to the present disclosure, an organic electroluminescent device can be provided which has low driving voltage and / or high luminous efficiency and / or long lifespan characteristics compared to conventional organic electroluminescent devices.

The invention relates to organic electroluminescent materials and devices. There is provided a compound having a first ligand LA comprising a structure of Formula I in which each of moieties A and B is a monocyclic or polycyclic fused ring system; at least one RA or RB has the structure of formula II, wherein the dashed line represents a bond to part A or part B, respectively; the part D is a polycyclic fused ring system; each of Z1 to Z4 and X1 to X5 is C or N; l is a direct bond or a linking group; y is a linking group; each of K1 and K2 is a direct bond or a linking group; and the dashed line of formula I is coordinated with the metal M. Formulations, OLEDs, and consumer products containing the compounds are also provided.

The present invention belongs to the technical field of organic materials, and provides a nitrogen-containing compound, an electronic element, and an electronic device. The structure of the nitrogen-containing compound is represented by formula 1, and the nitrogen-containing compound can improve the performance of the electronic element.

An organometallic compound represented by Formula 1:         Formula 1     M1(Ln1)n1(Ln2)n2 wherein M1 is a transition metal, Ln1 is a ligand represented by Formula 1A, Ln2 is a ligand represented by Formula 1B, n1 is 1 or 2, and n2 is 1 or 2: wherein ring CY4 is a polycyclic C5-C30 carbocyclic group or a polycyclic C1-C30 heterocyclic group; Y1 is O, S, or Se; Z1 is -Si(Q1)(Q2)(Q3) or -Ge(Q1)(Q2)(Q3); a1 is 1, 2, 3, or 4; at least one of R1 and R2 is a substituted or unsubstituted C1-C60 alkyl group, a substituted or unsubstituted C3-C10 cycloalkyl group, or a substituted or unsubstituted C6-C60 aryl group; and the remaining substituent groups are as defined herein.

The invention discloses thyroid hormone receptor beta subtype agonist derivatives, and a preparation method and application thereof.

A compound having a first ligand LA comprising a structure of Formula I,is provided. In Formula I, each of X1 to X8 is C or N; K is a direct bond or a linker; each RZ, Rα, Rβ, RA, and RB is hydrogen or a General Substituent defined herein; LA is coordinated to a metal M; and at least one of the following statements is true: (1) at least one RA is an electron-withdrawing group other than 4-fluorophenyl and no two RB substituents are joined or fused to form a benzofuran moiety with the furan fused to ring B; or (2) two RA are joined to form a 5-membered or 6-membered monocycle fused to ring A, and RZ and an RB substituent are joined to form a ring. Formulations, OLEDs, and consumer products containing the compound are also provided.

The present disclosure relates to a boron compound applicable to an organic light-emitting diode and an organic light-emitting diode comprising same. More specifically, the present disclosure relates to a boron compound represented by any one of Chemical Formulas A to D and an organic light-emitting diode comprising same, wherein Chemical Formulas A to D are as defined in the description.

The invention discloses a diisoprene derivative as shown in a structural general formula (I) and a structural general formula (II), or pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, the diisoprene derivative has the activity of regulating the expression of a low-density lipoprotein receptor (LDLR), and can inhibit tumor cell proliferation, control inflammatory factor release, inhibit tumor cell proliferation, inhibit tumor cell proliferation, inhibit tumor cell proliferation, inhibit tumor cell proliferation, inhibit tumor cell proliferation, inhibit tumor cell proliferation, inhibit tumor cell proliferation, inhibit tumor cell proliferation, inhibit tumor cell proliferation, inhibit tumor cell proliferation, inhibit tumor cell proliferation, inhibit tumor cell proliferation and inhibit tumor cell proliferation. The accumulation of retinal lipofuscin is reduced, macular degeneration is improved, and retinal injury is relieved. The diisoprene derivative can be used for treating diseases related to abnormal lipid metabolism, such as cardiovascular diseases, metabolic diseases, cancer, inflammation, retinal diseases and / or other diseases. # imgabs0 #